The study of primary immunodeficiencies or inborn errors of immunity continues to drive our
knowledge of the function of the human immune system. From the outset, the study of inborn …

Highlights•Challenges faced during ATMP development in academia.•Experience in
providing support to ATMP development by building and operating a pre-GMP core …

Objectives The uncertainty in the cost-benefit of advanced therapy medicinal products
(ATMPs) is a current challenge for their reimbursement in health systems. This study aimed …

Aims For patients with cartilage defects of the knee, a new biocompatible and in situ cross-
linkable albumin-hyaluronan-based hydrogel has been developed for matrix-associated …

Tissue-engineered products (TEPs) are at the forefront of developmental medicines,
precisely where monoclonal antibodies and recombinant cytokines were 30 years ago …

Importance Innovative nuclear medicine services offer substantial clinical value to patients.
However, these advancements often come with high costs. Traditional payment strategies …

The development of innovative biomedical technologies that use gene editing tools opens
up new possibilities in the treatment of rare diseases, as well as diseases that were not …

ObjectiveThis study examined the application, feasibility, and validity of supervised learning
models for text classification in appraisals for rare disease treatments (RDTs) in relation to …

There are two significant challenges for analysts conducting economic evaluations of
advanced therapy medicinal products (ATMPs):(1) estimating long-term treatment effects in …

Alternative formats If you require this document in an alternative format, please contact:
openaccess@bath.ac.uk Page 1 Citation for published version: McKenzie, CM, Chappell, J …